1 | reductions | 10,288 |
2 | prasugrel-thrombolysis | 17 |
3 | 5fu-aes | 4 |
4 | non-proportionality | 4 |
5 | hydrouretero-nephrosis | 3 |
6 | 2/115 | 2 |
7 | asthenia-cold | 2 |
8 | atherosclerosis-thrombolysis | 2 |
9 | biorhythms | 2 |
10 | cns=10.5 | 2 |
11 | coantioxidants | 2 |
12 | contestants | 2 |
13 | copp/abvd | 2 |
14 | dysplasia-carcinoma | 2 |
15 | gestodene/ethinylestradiol | 2 |
16 | ipp=12mmhg | 2 |
17 | kscn | 2 |
18 | nasosinusitis | 2 |
19 | neuropsychopathology | 2 |
20 | non-bf | 2 |
21 | non-ohss | 2 |
22 | proadm-levels | 2 |
23 | re-engaged | 2 |
24 | vancomycin-aztreonam | 2 |
25 | xchdg | 2 |
26 | 'difference | 1 |
27 | +0·10 | 1 |
28 | -3.53±0.22 | 1 |
29 | -4.1-fold | 1 |
30 | 0.814±0.179 | 1 |
31 | 1,5-fused-1,2,3-triazoles | 1 |
32 | 1-o-acetyl-2,3,5-tri-o-benzoyl-β-d-ribofuranose | 1 |
33 | 1.20±0.52 | 1 |
34 | 18/282 | 1 |
35 | 2,3-dichloro-5,6-dicyano-benzoquinone | 1 |
36 | 3-acetonylideneoxindole | 1 |
37 | 3-amino-2-oxoindolin-3-yl-phosphonates | 1 |
38 | 3-month-independence | 1 |
39 | 315.41 | 1 |
40 | 38/117 | 1 |
41 | 4-no2 | 1 |
42 | 5-10nm | 1 |
43 | 5ht3-antagonists | 1 |
44 | 6.15±1.24 | 1 |
45 | 7107 | 1 |
46 | 88/238 | 1 |
47 | acpa-positivity | 1 |
48 | aliases | 1 |
49 | alloplasts | 1 |
50 | ambisome®.patients | 1 |
51 | amr-all | 1 |
52 | anorexiant | 1 |
53 | anti-hbs≥100miu/ml | 1 |
54 | anti-ro/ss-a60 | 1 |
55 | antrumectomy | 1 |
56 | atg8s | 1 |
57 | athsp90.1-4 | 1 |
58 | branules | 1 |
59 | bupivcaine | 1 |
60 | cervarix™ | 1 |
61 | cfeom1a | 1 |
62 | change/recovery | 1 |
63 | cop/chop | 1 |
64 | culture-sensitivity | 1 |
65 | cyclophosphamide/mafosfamide | 1 |
66 | de-dimerization | 1 |
67 | doxotaxel | 1 |
68 | enhancedap | 1 |
69 | everolilmus | 1 |
70 | first-ovulation | 1 |
71 | fluconazole/itraconazole | 1 |
72 | fold-reduction | 1 |
73 | gsk3β1 | 1 |
74 | haemostats | 1 |
75 | hcv/1b | 1 |
76 | heat-flourishing | 1 |
77 | human-pcsk9 | 1 |
78 | imipinem-resistance | 1 |
79 | immunospecificity | 1 |
80 | improvement/deterioration | 1 |
81 | ketorolac/oxycodone | 1 |
82 | kindergarten-age | 1 |
83 | ln-auc | 1 |
84 | lovastain | 1 |
85 | markedness | 1 |
86 | mdi+smbg | 1 |
87 | metabochip | 1 |
88 | mgclr | 1 |
89 | microadjustments | 1 |
90 | mini-ureteroscopy | 1 |
91 | modulability | 1 |
92 | multi-functions | 1 |
93 | naod | 1 |
94 | narcolepsy/cataplexy | 1 |
95 | neccessity | 1 |
96 | neurosedation | 1 |
97 | nh4pf6 | 1 |
98 | nitrofuarntoin | 1 |
99 | non-attachment | 1 |
100 | nutd | 1 |
101 | oligohydroamnios | 1 |
102 | outlay | 1 |
103 | pain/pyrexia | 1 |
104 | pci.however | 1 |
105 | peginterferon-α2a/ribavirin | 1 |
106 | penicillin/ampicillin-chloramphenicol | 1 |
107 | pg2a | 1 |
108 | plasma-delta-9-tetrahydrocannabinol | 1 |
109 | pneumonía | 1 |
110 | pre-brochure | 1 |
111 | propofol-glucuronidation | 1 |
112 | rearrangement/dissociation | 1 |
113 | reducations | 1 |
114 | resorcinols/naphthols | 1 |
115 | rs2794520 | 1 |
116 | rs2847281 | 1 |
117 | rsba≥128 | 1 |
118 | rv-16 | 1 |
119 | scoring-results | 1 |
120 | sham-off | 1 |
121 | si2br6 | 1 |
122 | size-changes | 1 |
123 | society-at-large | 1 |
124 | statins-even | 1 |
125 | sulfametizole | 1 |
126 | t2-hyperintensity | 1 |
127 | tfaimcl | 1 |
128 | thinseeds | 1 |
129 | unbalances | 1 |
130 | visual-score | 1 |
131 | w105 | 1 |
132 | warfain | 1 |
133 | was.5 | 1 |
134 | wide-variability | 1 |
135 | £6400 | 1 |
136 | ω-3pufa | 1 |
1 | 'difference | 1 |
2 | +0·10 | 1 |
3 | -3.53±0.22 | 1 |
4 | -4.1-fold | 1 |
5 | 0.814±0.179 | 1 |
6 | 1,5-fused-1,2,3-triazoles | 1 |
7 | 1-o-acetyl-2,3,5-tri-o-benzoyl-β-d-ribofuranose | 1 |
8 | 1.20±0.52 | 1 |
9 | 18/282 | 1 |
10 | 2,3-dichloro-5,6-dicyano-benzoquinone | 1 |
11 | 2/115 | 2 |
12 | 3-acetonylideneoxindole | 1 |
13 | 3-amino-2-oxoindolin-3-yl-phosphonates | 1 |
14 | 3-month-independence | 1 |
15 | 315.41 | 1 |
16 | 38/117 | 1 |
17 | 4-no2 | 1 |
18 | 5-10nm | 1 |
19 | 5fu-aes | 4 |
20 | 5ht3-antagonists | 1 |
21 | 6.15±1.24 | 1 |
22 | 7107 | 1 |
23 | 88/238 | 1 |
24 | acpa-positivity | 1 |
25 | aliases | 1 |
26 | alloplasts | 1 |
27 | ambisome®.patients | 1 |
28 | amr-all | 1 |
29 | anorexiant | 1 |
30 | anti-hbs≥100miu/ml | 1 |
31 | anti-ro/ss-a60 | 1 |
32 | antrumectomy | 1 |
33 | asthenia-cold | 2 |
34 | atg8s | 1 |
35 | atherosclerosis-thrombolysis | 2 |
36 | athsp90.1-4 | 1 |
37 | biorhythms | 2 |
38 | branules | 1 |
39 | bupivcaine | 1 |
40 | cervarix™ | 1 |
41 | cfeom1a | 1 |
42 | change/recovery | 1 |
43 | cns=10.5 | 2 |
44 | coantioxidants | 2 |
45 | contestants | 2 |
46 | cop/chop | 1 |
47 | copp/abvd | 2 |
48 | culture-sensitivity | 1 |
49 | cyclophosphamide/mafosfamide | 1 |
50 | de-dimerization | 1 |
51 | doxotaxel | 1 |
52 | dysplasia-carcinoma | 2 |
53 | enhancedap | 1 |
54 | everolilmus | 1 |
55 | first-ovulation | 1 |
56 | fluconazole/itraconazole | 1 |
57 | fold-reduction | 1 |
58 | gestodene/ethinylestradiol | 2 |
59 | gsk3β1 | 1 |
60 | haemostats | 1 |
61 | hcv/1b | 1 |
62 | heat-flourishing | 1 |
63 | human-pcsk9 | 1 |
64 | hydrouretero-nephrosis | 3 |
65 | imipinem-resistance | 1 |
66 | immunospecificity | 1 |
67 | improvement/deterioration | 1 |
68 | ipp=12mmhg | 2 |
69 | ketorolac/oxycodone | 1 |
70 | kindergarten-age | 1 |
71 | kscn | 2 |
72 | ln-auc | 1 |
73 | lovastain | 1 |
74 | markedness | 1 |
75 | mdi+smbg | 1 |
76 | metabochip | 1 |
77 | mgclr | 1 |
78 | microadjustments | 1 |
79 | mini-ureteroscopy | 1 |
80 | modulability | 1 |
81 | multi-functions | 1 |
82 | naod | 1 |
83 | narcolepsy/cataplexy | 1 |
84 | nasosinusitis | 2 |
85 | neccessity | 1 |
86 | neuropsychopathology | 2 |
87 | neurosedation | 1 |
88 | nh4pf6 | 1 |
89 | nitrofuarntoin | 1 |
90 | non-attachment | 1 |
91 | non-bf | 2 |
92 | non-ohss | 2 |
93 | non-proportionality | 4 |
94 | nutd | 1 |
95 | oligohydroamnios | 1 |
96 | outlay | 1 |
97 | pain/pyrexia | 1 |
98 | pci.however | 1 |
99 | peginterferon-α2a/ribavirin | 1 |
100 | penicillin/ampicillin-chloramphenicol | 1 |
101 | pg2a | 1 |
102 | plasma-delta-9-tetrahydrocannabinol | 1 |
103 | pneumonía | 1 |
104 | prasugrel-thrombolysis | 17 |
105 | pre-brochure | 1 |
106 | proadm-levels | 2 |
107 | propofol-glucuronidation | 1 |
108 | re-engaged | 2 |
109 | rearrangement/dissociation | 1 |
110 | reducations | 1 |
111 | reductions | 10,288 |
112 | resorcinols/naphthols | 1 |
113 | rs2794520 | 1 |
114 | rs2847281 | 1 |
115 | rsba≥128 | 1 |
116 | rv-16 | 1 |
117 | scoring-results | 1 |
118 | sham-off | 1 |
119 | si2br6 | 1 |
120 | size-changes | 1 |
121 | society-at-large | 1 |
122 | statins-even | 1 |
123 | sulfametizole | 1 |
124 | t2-hyperintensity | 1 |
125 | tfaimcl | 1 |
126 | thinseeds | 1 |
127 | unbalances | 1 |
128 | vancomycin-aztreonam | 2 |
129 | visual-score | 1 |
130 | w105 | 1 |
131 | warfain | 1 |
132 | was.5 | 1 |
133 | wide-variability | 1 |
134 | xchdg | 2 |
135 | £6400 | 1 |
136 | ω-3pufa | 1 |
1 | £6400 | 1 |
2 | +0·10 | 1 |
3 | rs2794520 | 1 |
4 | anti-ro/ss-a60 | 1 |
5 | 315.41 | 1 |
6 | rs2847281 | 1 |
7 | gsk3β1 | 1 |
8 | -3.53±0.22 | 1 |
9 | 1.20±0.52 | 1 |
10 | 18/282 | 1 |
11 | 4-no2 | 1 |
12 | athsp90.1-4 | 1 |
13 | 6.15±1.24 | 1 |
14 | cns=10.5 | 2 |
15 | was.5 | 1 |
16 | w105 | 1 |
17 | 2/115 | 2 |
18 | rv-16 | 1 |
19 | nh4pf6 | 1 |
20 | si2br6 | 1 |
21 | 7107 | 1 |
22 | 38/117 | 1 |
23 | rsba≥128 | 1 |
24 | 88/238 | 1 |
25 | 0.814±0.179 | 1 |
26 | human-pcsk9 | 1 |
27 | cfeom1a | 1 |
28 | pg2a | 1 |
29 | ω-3pufa | 1 |
30 | pain/pyrexia | 1 |
31 | dysplasia-carcinoma | 2 |
32 | pneumonía | 1 |
33 | hcv/1b | 1 |
34 | ln-auc | 1 |
35 | re-engaged | 2 |
36 | asthenia-cold | 2 |
37 | -4.1-fold | 1 |
38 | naod | 1 |
39 | nutd | 1 |
40 | copp/abvd | 2 |
41 | imipinem-resistance | 1 |
42 | 3-month-independence | 1 |
43 | 'difference | 1 |
44 | cyclophosphamide/mafosfamide | 1 |
45 | kindergarten-age | 1 |
46 | society-at-large | 1 |
47 | 3-acetonylideneoxindole | 1 |
48 | fluconazole/itraconazole | 1 |
49 | sulfametizole | 1 |
50 | bupivcaine | 1 |
51 | ketorolac/oxycodone | 1 |
52 | 2,3-dichloro-5,6-dicyano-benzoquinone | 1 |
53 | visual-score | 1 |
54 | pre-brochure | 1 |
55 | 1-o-acetyl-2,3,5-tri-o-benzoyl-β-d-ribofuranose | 1 |
56 | non-bf | 2 |
57 | sham-off | 1 |
58 | mdi+smbg | 1 |
59 | xchdg | 2 |
60 | ipp=12mmhg | 2 |
61 | heat-flourishing | 1 |
62 | tfaimcl | 1 |
63 | doxotaxel | 1 |
64 | amr-all | 1 |
65 | anti-hbs≥100miu/ml | 1 |
66 | penicillin/ampicillin-chloramphenicol | 1 |
67 | gestodene/ethinylestradiol | 2 |
68 | plasma-delta-9-tetrahydrocannabinol | 1 |
69 | vancomycin-aztreonam | 2 |
70 | 5-10nm | 1 |
71 | kscn | 2 |
72 | statins-even | 1 |
73 | warfain | 1 |
74 | lovastain | 1 |
75 | nitrofuarntoin | 1 |
76 | peginterferon-α2a/ribavirin | 1 |
77 | neurosedation | 1 |
78 | propofol-glucuronidation | 1 |
79 | rearrangement/dissociation | 1 |
80 | first-ovulation | 1 |
81 | improvement/deterioration | 1 |
82 | de-dimerization | 1 |
83 | fold-reduction | 1 |
84 | enhancedap | 1 |
85 | metabochip | 1 |
86 | cop/chop | 1 |
87 | pci.however | 1 |
88 | mgclr | 1 |
89 | atg8s | 1 |
90 | thinseeds | 1 |
91 | 5fu-aes | 4 |
92 | unbalances | 1 |
93 | size-changes | 1 |
94 | 1,5-fused-1,2,3-triazoles | 1 |
95 | branules | 1 |
96 | aliases | 1 |
97 | 3-amino-2-oxoindolin-3-yl-phosphonates | 1 |
98 | hydrouretero-nephrosis | 3 |
99 | prasugrel-thrombolysis | 17 |
100 | atherosclerosis-thrombolysis | 2 |
101 | nasosinusitis | 2 |
102 | proadm-levels | 2 |
103 | resorcinols/naphthols | 1 |
104 | biorhythms | 2 |
105 | reducations | 1 |
106 | multi-functions | 1 |
107 | reductions | 10,288 |
108 | oligohydroamnios | 1 |
109 | markedness | 1 |
110 | non-ohss | 2 |
111 | haemostats | 1 |
112 | scoring-results | 1 |
113 | coantioxidants | 2 |
114 | contestants | 2 |
115 | ambisome®.patients | 1 |
116 | microadjustments | 1 |
117 | alloplasts | 1 |
118 | 5ht3-antagonists | 1 |
119 | everolilmus | 1 |
120 | anorexiant | 1 |
121 | non-attachment | 1 |
122 | outlay | 1 |
123 | neuropsychopathology | 2 |
124 | antrumectomy | 1 |
125 | mini-ureteroscopy | 1 |
126 | change/recovery | 1 |
127 | immunospecificity | 1 |
128 | non-proportionality | 4 |
129 | wide-variability | 1 |
130 | modulability | 1 |
131 | t2-hyperintensity | 1 |
132 | neccessity | 1 |
133 | culture-sensitivity | 1 |
134 | acpa-positivity | 1 |
135 | narcolepsy/cataplexy | 1 |
136 | cervarix™ | 1 |